U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C8H11NO3
Molecular Weight 169.1778
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PYRIDOXINE

SMILES

CC1=NC=C(CO)C(CO)=C1O

InChI

InChIKey=LXNHXLLTXMVWPM-UHFFFAOYSA-N
InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3

HIDE SMILES / InChI

Molecular Formula C8H11NO3
Molecular Weight 169.1778
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: Description was created based on several sources, including https://www.drugs.com/pro/pyridoxine-hydrochloride-injection.html

Pyridoxine is the 4-methanol form of vitamin B6 and is converted to pyridoxal 5-phosphate in the body. Vitamin B6 (pyridoxine) is a water-soluble vitamin used in the prophylaxis and treatment of vitamin B6 deficiency and peripheral neuropathy in those receiving isoniazid (isonicotinic acid hydrazide, INH). Vitamin B6 has been found to lower systolic and diastolic blood pressure in a small group of subjects with essential hypertension. Hypertension is another risk factor for atherosclerosis and coronary heart disease. Another study showed pyridoxine hydrochloride to inhibit ADP- or epinephrine-induced platelet aggregation and to lower total cholesterol levels and increase HDL-cholesterol levels, again in a small group of subjects. Vitamin B6, in the form of pyridoxal 5'-phosphate, was found to protect vascular endothelial cells in culture from injury by activated platelets. Endothelial injury and dysfunction are critical initiating events in the pathogenesis of atherosclerosis. Human studies have demonstrated that vitamin B6 deficiency affects cellular and humoral responses of the immune system. Vitamin B6 deficiency results in altered lymphocyte differentiation and maturation, reduced delayed-type hypersensitivity (DTH) responses, impaired antibody production, decreased lymphocyte proliferation and decreased interleukin (IL)-2 production, among other immunologic activities. Used for the treatment of vitamin B6 deficiency and for the prophylaxis of isoniazid-induced peripheral neuropathy.

Originator

Curator's Comment: The combination of doxylamine and vitamin B6 (PYRIDOXINE) was first introduced to the US market as Bendectin in 1956 by the Wm. S. Merrell Company of Cincinnati, Ohio.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.3 mM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Primary
PYRIDOXINE HYDROCHLORIDE

Approved Use

Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia.

Launch Date

1972
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
189.6 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
58.9 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
62 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
33.1 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
2183.2 nM
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXAL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
48.2 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
12.7 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
38.9 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
47.1 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
372.7 nM
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
85.9 ng/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
30.1 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
27.4 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
30.2 ng/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
892.9 nM
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1750.3 nM
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
4-PYRIDOXIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1511.3 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
233.6 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
244 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
249.2 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
18603.4 nM × h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXAL plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
80 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
27 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
35.1 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
42.5 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
2008.9 nM × h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
1742.3 ng × h/mL
20 mg 2 times / day multiple, oral
dose: 20 mg
route of administration: Oral
experiment type: MULTIPLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: UNKNOWN
1076.2 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1021.7 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
1064.6 ng × h/mL
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
19420.2 nM × h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
PYRIDOXAL PHOSPHATE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
18543.1 nM × h
100 mg single, intravenous
dose: 100 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
4-PYRIDOXIC ACID plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
8 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
12.5 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXAL blood
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
1.2 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: HIGH-FAT
0.4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
0.4 h
20 mg single, oral
dose: 20 mg
route of administration: Oral
experiment type: SINGLE
co-administered: DOXYLAMINE SUCCINATE
PYRIDOXINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
doxylamine succinate(10 mg; 2 per day (up to 4))
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
pregnant, mean age 26 years
n = 133
Health Status: pregnant
Age Group: mean age 26 years
Sex: F
Population Size: 133
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
Disc. AE: Somnolence, Syncope...
AEs leading to
discontinuation/dose reduction:
Somnolence (1.5%)
Syncope (0.7%)
Dizziness (0.7%)
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
117 mg multiple, oral (mean)
Studied dose
Dose: 117 mg
Route: oral
Route: multiple
Dose: 117 mg
Sources:
unhealthy, mean age 41.5 years
n = 172
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 41.5 years
Sex: F
Population Size: 172
Sources:
Disc. AE: Paraesthesia, Muscle weakness...
AEs leading to
discontinuation/dose reduction:
Paraesthesia (34%)
Muscle weakness (19.2%)
Numbness (12.2%)
Sources:
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Disc. AE: Depression, Headache...
AEs leading to
discontinuation/dose reduction:
Depression (79%)
Headache (48%)
Tiredness (59%)
Irritability (38%)
Neuropathy (40%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Dizziness 0.7%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
doxylamine succinate(10 mg; 2 per day (up to 4))
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
pregnant, mean age 26 years
n = 133
Health Status: pregnant
Age Group: mean age 26 years
Sex: F
Population Size: 133
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
Syncope 0.7%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
doxylamine succinate(10 mg; 2 per day (up to 4))
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
pregnant, mean age 26 years
n = 133
Health Status: pregnant
Age Group: mean age 26 years
Sex: F
Population Size: 133
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
Somnolence 1.5%
Disc. AE
10 mg 2 times / day multiple, oral
Recommended
Dose: 10 mg, 2 times / day
Route: oral
Route: multiple
Dose: 10 mg, 2 times / day
Co-administed with::
doxylamine succinate(10 mg; 2 per day (up to 4))
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
pregnant, mean age 26 years
n = 133
Health Status: pregnant
Age Group: mean age 26 years
Sex: F
Population Size: 133
Sources: Page: nda/2013/021876Orig1s000MedR.pdf - p.82
Numbness 12.2%
Disc. AE
117 mg multiple, oral (mean)
Studied dose
Dose: 117 mg
Route: oral
Route: multiple
Dose: 117 mg
Sources:
unhealthy, mean age 41.5 years
n = 172
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 41.5 years
Sex: F
Population Size: 172
Sources:
Muscle weakness 19.2%
Disc. AE
117 mg multiple, oral (mean)
Studied dose
Dose: 117 mg
Route: oral
Route: multiple
Dose: 117 mg
Sources:
unhealthy, mean age 41.5 years
n = 172
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 41.5 years
Sex: F
Population Size: 172
Sources:
Paraesthesia 34%
Disc. AE
117 mg multiple, oral (mean)
Studied dose
Dose: 117 mg
Route: oral
Route: multiple
Dose: 117 mg
Sources:
unhealthy, mean age 41.5 years
n = 172
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 41.5 years
Sex: F
Population Size: 172
Sources:
Irritability 38%
Disc. AE
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Neuropathy 40%
Disc. AE
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Headache 48%
Disc. AE
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Tiredness 59%
Disc. AE
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Depression 79%
Disc. AE
175 mg multiple, oral
Studied dose
Dose: 175 mg
Route: oral
Route: multiple
Dose: 175 mg
Sources:
unhealthy, mean age 42 years
n = 58
Health Status: unhealthy
Condition: premenstrual syndrome
Age Group: mean age 42 years
Sex: F
Population Size: 58
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer

Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
yes
PubMed

PubMed

TitleDatePubMed
Clinical and institutional aspects of antidote therapy in Russia.
2001
Drug treatment for tuberculosis during pregnancy: safety considerations.
2001
[Effects of biologically active supplements on the antioxidant and vitamin status of patients with hypertension and ischemic heart disease].
2001
Effects of vitamins on hepatic nuclear binding of L-tryptophan.
2001
Influence of a probiotic yoghurt on the status of vitamins B(1), B(2) and B(6) in the healthy adult human.
2001
[Determination of 4-O-methylpyridoxine (MPN) by HPLC with diode-array detector].
2001 Apr
Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
2001 Apr
Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease.
2001 Apr
Vitamin supplementation and pregnancy outcome in women with recurrent early pregnancy loss and hyperhomocysteinemia.
2001 Apr
Effect of energy restriction and exercise on vitamin B-6 status of women during lactation.
2001 Apr
Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients.
2001 Apr
Association of the B-vitamins pyridoxal 5'-phosphate (B(6)), B(12), and folate with lung cancer risk in older men.
2001 Apr 1
Effects of short-term dietary administration of marginal levels of vitamin B(6)and fish oil on lipid composition and antioxidant defences in rat tissues.
2001 Apr-May
Experimental model of pyridoxine (B6) deficiency-induced neuropathy.
2001 Aug
The safety of higher than standard dose of doxylamine-pyridoxine (Diclectin) for nausea and vomiting of pregnancy.
2001 Aug
Homocysteine levels in patients treated with lipid apheresis: effect of a vitamin therapy.
2001 Aug
Homocysteine, fibrinogen, and lipoprotein(a) levels are simultaneously reduced in patients with chronic renal failure treated with folic acid, pyridoxine, and cyanocobalamin.
2001 Feb
Vitamin Intervention for Stroke Prevention (VISP) trial: rationale and design.
2001 Feb
Improved risk assessment by screening sperm parameters.
2001 Feb 28
[Acute isoniazid poisoning presenting convulsion and liver dysfunction].
2001 Jan
Certification of B-group vitamins (B1, B2, B6, and B12) in four food reference materials.
2001 Jan
Effects of long-term parenteral administration of vitamin B6 on B6 status and some aspects of the glucose and protein metabolism of early-weaned piglets.
2001 Jan
Phylogenetic analyses and comparative genomics of vitamin B6 (pyridoxine) and pyridoxal phosphate biosynthesis pathways.
2001 Jan
Abnormal vitamin B6 metabolism in alkaline phosphatase knock-out mice causes multiple abnormalities, but not the impaired bone mineralization.
2001 Jan
Hyperhomocysteinemia in renal transplant patients: an independent factor of cardiovascular disease.
2001 Jan-Feb
Long-term effects of vitamin B(12), folate, and vitamin B(6) supplements in elderly people with normal serum vitamin B(12) concentrations.
2001 Jan-Feb
Effects of glucose, vitamins, and DO concentrations on pyruvate fermentation using Torulopsis glabrata IFO 0005 with metabolic flux analysis.
2001 Jan-Feb
Homocysteine--a treatable risk factor for allograft vascular disease after heart transplantation?
2001 Jul
Intravenous pyridoxine-induced metabolic acidosis.
2001 Jul
Multi-task flow system for potentiometric analysis: its application to the determination of vitamin B6 in pharmaceuticals.
2001 Jul
Pyridoxine-dependent and pyridoxine-responsive seizures.
2001 Jun
Blood determinations of S-adenosylmethionine, S-adenosylhomocysteine, and homocysteine: correlations with diet.
2001 Jun
Sensitivity to meat protein intake and hyperoxaluria in idiopathic calcium stone formers.
2001 Jun
Impaired heme binding and aggregation of mutant cystathionine beta-synthase subunits in homocystinuria.
2001 Jun
Light-dependent generation of reactive oxygen species in cell culture media.
2001 Jun 15
Risk and uncertainty.
2001 Jun 21
Low dietary folate intake is associated with an excess incidence of acute coronary events: The Kuopio Ischemic Heart Disease Risk Factor Study.
2001 Jun 5
Homocyst(e)ine metabolism in hemodialysis patients treated with vitamins B6, B12 and folate.
2001 Mar
Effective treatment of hyperhomocysteinemia in heart transplant recipients with and without renal failure.
2001 Mar
Hyperhomocysteinemia enhances vascular inflammation and accelerates atherosclerosis in a murine model.
2001 Mar
Analysis of the pdx-1 (snz-1/sno-1) region of the Neurospora crassa genome: correlation of pyridoxine-requiring phenotypes with mutations in two structural genes.
2001 Mar
CSF glutamate/GABA concentrations in pyridoxine-dependent seizures: etiology of pyridoxine-dependent seizures and the mechanisms of pyridoxine action in seizure control.
2001 Mar
Occupational and systemic contact dermatitis with photosensitivity due to vitamin B6.
2001 Mar
Structural basis for the function of pyridoxine 5'-phosphate synthase.
2001 Mar 7
[Homocysteine metabolism and risk of cardiovascular diseases: importance of the nutritional status on folic acid, vitamins B6 and B12].
2001 Mar-Apr
[Antidepressive effect of pyridoxine (vitamin B6) in neuroleptic-treated schizophrenic patients with co-morbid minor depression--preliminary open-label trial].
2001 May
Homocysteine--an innocent bystander in vascular disease?
2001 May
Disposition of homocysteine in subjects heterozygous for homocystinuria due to cystathionine beta-synthase deficiency: relationship between genotype and phenotype.
2001 May 1
Plasma total cysteine as a risk factor for vascular disease: The European Concerted Action Project.
2001 May 29
Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.
2001 Sep
Patents

Sample Use Guides

Usual Adult Dose for Dietary Supplement Pyridoxine Deficiency: 10 to 25 mg/day orally, IM, or IV for 3 weeks followed by 2 to 5 mg/day from a multivitamin product. Usual Adult Dose for Anemia Sideroblastic, hereditary: 200 to 600 mg orally daily. If adequate response obtained, dose may be decreased to 30 to 50 mg orally daily.
Route of Administration: Other
Pyridoxine (5 mmol/l) caused complete inhibition of microvessel outgrowth in rat aortic rings
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:06:15 GMT 2023
Edited
by admin
on Fri Dec 15 15:06:15 GMT 2023
Record UNII
KV2JZ1BI6Z
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PYRIDOXINE
INCI   INN   MI   ORANGE BOOK   VANDF   WHO-DD  
INN   INCI  
Official Name English
PYRIDOXOL
Common Name English
ADERMINE
Common Name English
HEXABIONE
Common Name English
PYRIDOXINE [ORANGE BOOK]
Common Name English
PYRIDOXINE [VANDF]
Common Name English
VITAMIN V6
Brand Name English
4,5-BIS(HYDROXYMETHYL)-2-METHYLPYRIDIN-3-OL
Systematic Name English
NSC-759148
Code English
VITAMIN B-6
Common Name English
PYRIDOXINE [MI]
Common Name English
VITAMIN B6 [VANDF]
Common Name English
3,4-PYRIDINEDIMETHANOL, 5-HYDROXY-6-METHYL-
Systematic Name English
Pyridoxine [WHO-DD]
Common Name English
PYRIDOXINE [INCI]
Common Name English
pyridoxine [INN]
Common Name English
VITAMIN B6
VANDF  
Common Name English
Classification Tree Code System Code
LOINC 26915-9
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
LOINC 2900-9
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
NDF-RT N0000192800
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
EU-Orphan Drug EU/3/16/1673
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
LIVERTOX 1035
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 27
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
LIVERTOX NBK548710
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
DSLD 3308 (Number of products:6)
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
DSLD 3377 (Number of products:257)
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
WHO-ATC J04AM08
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
FDA ORPHAN DRUG 334311
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
LOINC 75043-0
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
NCI_THESAURUS C1334
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
WHO-VATC QA11HA02
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
CFR 21 CFR 102.23
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
LOINC 39786-9
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
WHO-ATC A11HA02
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
DSLD 2695 (Number of products:1886)
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
DSLD 110 (Number of products:1286)
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
Code System Code Type Description
SMS_ID
100000080848
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
FDA UNII
KV2JZ1BI6Z
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
INN
2216
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-603-0
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
CHEBI
16709
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
NSC
759148
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
RXCUI
684879
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
ChEMBL
CHEMBL1364
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
EPA CompTox
DTXSID4023541
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
PUBCHEM
1054
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
MERCK INDEX
m9365
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY Merck Index
NCI_THESAURUS
C62619
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
WIKIPEDIA
PYRIDOXINE
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
EVMPD
SUB10168MIG
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
RXCUI
42954
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
ALTERNATIVE
MESH
D011736
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
DAILYMED
KV2JZ1BI6Z
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
CHEBI
27306
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
DRUG CENTRAL
2836
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
CAS
65-23-6
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
EVMPD
SUB126944
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
DRUG BANK
DB00165
Created by admin on Fri Dec 15 15:06:15 GMT 2023 , Edited by admin on Fri Dec 15 15:06:15 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
PARENT -> CONSTITUENT ALWAYS PRESENT
Nutritional value per 100 g (3.5 oz) - 0.639 mg (4%)
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
METABOLITE ACTIVE -> PARENT
MAJOR
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC Elimination
PHARMACOKINETIC